Brian Kearney - 01 Feb 2023 Form 4 Insider Report for PARDES BIOSCIENCES, INC.

Reporting relationship: Chief Development Officer
Issuer ticker: N/A
Reported as of: 01 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2023, 15:30:38 UTC
Prior SEC filing: 16 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Lacy, attorney-in-fact

Key filing fact

Brian Kearney filed Form 4 for PARDES BIOSCIENCES, INC. on 03 Feb 2023.

Key facts

This page summarizes Brian Kearney's Form 4 filing for PARDES BIOSCIENCES, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2023, 15:30.

Change

Previous filing in this sequence was filed on 16 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRDS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +156,250
Change %
Price: $0.000000
Shares after: 156,250
Date: 01 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 156,250
Exercise price: $2.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 1st day of each month after the Grant Date (02/01/2023), subject to continued service relationship.